Skip to main content
Top
Published in: World Journal of Surgery 1/2017

01-01-2017 | Original Scientific Report

Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer

Authors: Gaya Spolverato, Fabio Bagante, Cecilia G. Ethun, George Poultsides, Thuy Tran, Kamran Idrees, Chelsea A. Isom, Ryan C. Fields, Bradley Krasnick, Emily Winslow, Clifford Cho, Robert C. G. Martin, Charles R. Scoggins, Perry Shen, Harveshp D. Mogal, Carl Schmidt, Eliza Beal, Ioannis Hatzaras, Rivfka Shenoy, Shishir K. Maithel, Timothy M. Pawlik

Published in: World Journal of Surgery | Issue 1/2017

Login to get access

Abstract

Background

While surgery offers the best curative-intent treatment, many patients with biliary tract malignancies have poor long-term outcomes. We sought to apply a non-mixture cure model to calculate the cure fraction and the time to cure after surgery of patients with peri-hilar cholangiocarcinoma (PHCC) or gallbladder cancer (GBC).

Methods

Using the Extrahepatic Biliary Malignancy Consortium, 576 patients who underwent curative-intent surgery for gallbladder carcinoma or peri-hilar cholangiocarcinoma between 1998 and 2014 at 10 major hepatobiliary institutions were identified and included in the analysis. A non-mixture cure model was adopted to compare mortality after surgery to the mortality expected for the general population matched by sex and age.

Results

The median and 5-year overall survival (OS) were 1.9 years (IQR, 0.9–4.9) and 23.9 % (95 % CI, 19.6–28.6). Among all patients with PHCC or GBC, the probability of being cured after surgery was 14.5 % (95 % CI, 8.7–23.2); the time to cure was 9.7 years and the median survival of uncured patients was 1.8 years. Determinants of cure probabilities included lymph node metastasis and CA 19.9 level (p ≤ 0.05). The cure fraction for patients with a CA 19.9 < 50 U/ml and no lymph nodes metastases were 39.0 % versus only 5.1 % among patients with a CA 19.9 ≥ 50 who also had lymph node metastasis.

Conclusions

Examining an “all comer” cohort, <15 % of patients with PHCC or GBC could be considered cured after surgery. Factors such CA 19.9 level and lymph node metastasis independently predicted long-term outcome. Estimating the odds of statistical cure following surgery for biliary tract cancer can assist in decision-making as well as inform discussions around survivorship.
Appendix
Available only for authorised users
Literature
1.
3.
go back to reference Hansel DE et al (2003) Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 163(1):217–229CrossRefPubMedPubMedCentral Hansel DE et al (2003) Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 163(1):217–229CrossRefPubMedPubMedCentral
5.
go back to reference Valle J et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281CrossRefPubMed Valle J et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281CrossRefPubMed
6.
go back to reference Friend E et al (2011) Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. Br J Cancer 104(4):587–592CrossRefPubMedPubMedCentral Friend E et al (2011) Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. Br J Cancer 104(4):587–592CrossRefPubMedPubMedCentral
7.
go back to reference El-Khoueiry AB et al (2012) SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 30(4):1646–1651CrossRefPubMed El-Khoueiry AB et al (2012) SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 30(4):1646–1651CrossRefPubMed
8.
go back to reference El-Khoueiry AB et al (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110(4):882–887CrossRefPubMedPubMedCentral El-Khoueiry AB et al (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110(4):882–887CrossRefPubMedPubMedCentral
9.
go back to reference Ben-Josef E et al (2015) SWOG S0809: a Phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol 33(24):2617–2622CrossRefPubMed Ben-Josef E et al (2015) SWOG S0809: a Phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol 33(24):2617–2622CrossRefPubMed
10.
go back to reference Jarnagin WR et al (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234(4):507–517 (discussion 517–519) CrossRefPubMedPubMedCentral Jarnagin WR et al (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234(4):507–517 (discussion 517–519) CrossRefPubMedPubMedCentral
11.
12.
go back to reference Mao K et al (2016) Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol 31(2):417–426CrossRefPubMedPubMedCentral Mao K et al (2016) Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol 31(2):417–426CrossRefPubMedPubMedCentral
13.
go back to reference Wang J et al (2015) Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: a multi-institutional experience. Ann Surg Oncol 22(Suppl 3):1100–1106CrossRef Wang J et al (2015) Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: a multi-institutional experience. Ann Surg Oncol 22(Suppl 3):1100–1106CrossRef
14.
go back to reference Hueman MT, Vollmer CM Jr, Pawlik TM (2009) Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol 16(8):2101–2115CrossRefPubMed Hueman MT, Vollmer CM Jr, Pawlik TM (2009) Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol 16(8):2101–2115CrossRefPubMed
15.
go back to reference Amini N et al (2015) Lymph node status after resection for gallbladder adenocarcinoma: prognostic implications of different nodal staging/scoring systems. J Surg Oncol 111(3):299–305CrossRefPubMed Amini N et al (2015) Lymph node status after resection for gallbladder adenocarcinoma: prognostic implications of different nodal staging/scoring systems. J Surg Oncol 111(3):299–305CrossRefPubMed
16.
go back to reference Weiss MJ et al (2014) Multimodal treatment strategies for advanced hilar cholangiocarcinoma. Langenbecks Arch Surg 399(6):679–692CrossRefPubMed Weiss MJ et al (2014) Multimodal treatment strategies for advanced hilar cholangiocarcinoma. Langenbecks Arch Surg 399(6):679–692CrossRefPubMed
18.
go back to reference Maetani S, Gamel JW (2010) Evolution of cancer survival analysis. Surg Oncol 19(2):49–51 (discussion 61) CrossRefPubMed Maetani S, Gamel JW (2010) Evolution of cancer survival analysis. Surg Oncol 19(2):49–51 (discussion 61) CrossRefPubMed
19.
go back to reference Lambert PC et al (2007) Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics 8(3):576–594CrossRefPubMed Lambert PC et al (2007) Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics 8(3):576–594CrossRefPubMed
20.
go back to reference Cvancarova M et al (2013) Proportion cured models applied to 23 cancer sites in Norway. Int J Cancer 132(7):1700–1710CrossRefPubMed Cvancarova M et al (2013) Proportion cured models applied to 23 cancer sites in Norway. Int J Cancer 132(7):1700–1710CrossRefPubMed
21.
go back to reference Dal Maso L et al (2014) Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. Ann Oncol 25(11):2251–2260CrossRefPubMedPubMedCentral Dal Maso L et al (2014) Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. Ann Oncol 25(11):2251–2260CrossRefPubMedPubMedCentral
22.
go back to reference Spolverato G et al (2015) Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer 121(22):3998–4006CrossRefPubMed Spolverato G et al (2015) Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer 121(22):3998–4006CrossRefPubMed
23.
go back to reference Edge SB, Byrd D, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York Edge SB, Byrd D, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York
24.
go back to reference Mayo SC et al (2011) Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford) 13(7):473–482CrossRef Mayo SC et al (2011) Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford) 13(7):473–482CrossRef
25.
go back to reference Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRefPubMedPubMedCentral
27.
go back to reference Tsodikov AD, Ibrahim JG, Yakovlev AY (2003) Estimating cure rates from survival data: an alternative to two-component mixture models. J Am Stat Assoc 98(464):1063–1078CrossRefPubMedPubMedCentral Tsodikov AD, Ibrahim JG, Yakovlev AY (2003) Estimating cure rates from survival data: an alternative to two-component mixture models. J Am Stat Assoc 98(464):1063–1078CrossRefPubMedPubMedCentral
29.
go back to reference Miyazaki M et al (2015) Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. J Hepatobiliary Pancreat Sci 22(4):249–273CrossRefPubMed Miyazaki M et al (2015) Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. J Hepatobiliary Pancreat Sci 22(4):249–273CrossRefPubMed
30.
go back to reference Chan E, Berlin J (2015) Biliary tract cancers: understudied and poorly understood. J Clin Oncol 33(16):1845–1848CrossRefPubMed Chan E, Berlin J (2015) Biliary tract cancers: understudied and poorly understood. J Clin Oncol 33(16):1845–1848CrossRefPubMed
32.
go back to reference Kim Y et al (2015) Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. Cancer 121(20):3564–3573CrossRefPubMedPubMedCentral Kim Y et al (2015) Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. Cancer 121(20):3564–3573CrossRefPubMedPubMedCentral
33.
go back to reference Pawlik TM et al (2014) What are patients’ expectations about the effects of chemotherapy for advanced cancer? J Am Coll Surg 219(3):588–590CrossRefPubMed Pawlik TM et al (2014) What are patients’ expectations about the effects of chemotherapy for advanced cancer? J Am Coll Surg 219(3):588–590CrossRefPubMed
34.
go back to reference Cai C et al (2012) smcure: an R-package for estimating semiparametric mixture cure models. Comput Methods Progr Biomed 108(3):1255–1260CrossRef Cai C et al (2012) smcure: an R-package for estimating semiparametric mixture cure models. Comput Methods Progr Biomed 108(3):1255–1260CrossRef
35.
go back to reference De Angelis R et al (1999) Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med 18(4):441–454CrossRefPubMed De Angelis R et al (1999) Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med 18(4):441–454CrossRefPubMed
36.
go back to reference Cai WK et al (2014) Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma. Int J Clin Exp Pathol 7(11):7890–7898PubMedPubMedCentral Cai WK et al (2014) Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma. Int J Clin Exp Pathol 7(11):7890–7898PubMedPubMedCentral
38.
go back to reference Goere D et al (2013) Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 257(6):1065–1071CrossRefPubMed Goere D et al (2013) Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 257(6):1065–1071CrossRefPubMed
39.
go back to reference Hosokawa I et al (2016) Long-term survival benefit and potential for cure after R1 resection for colorectal liver metastases. Ann Surg Oncol 23(6):1897–1905CrossRefPubMed Hosokawa I et al (2016) Long-term survival benefit and potential for cure after R1 resection for colorectal liver metastases. Ann Surg Oncol 23(6):1897–1905CrossRefPubMed
40.
go back to reference Rama R, Swaminathan R, Venkatesan P (2010) Cure models for estimating hospital-based breast cancer survival. Asian Pac J Cancer Prev 11(2):387–391PubMed Rama R, Swaminathan R, Venkatesan P (2010) Cure models for estimating hospital-based breast cancer survival. Asian Pac J Cancer Prev 11(2):387–391PubMed
Metadata
Title
Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer
Authors
Gaya Spolverato
Fabio Bagante
Cecilia G. Ethun
George Poultsides
Thuy Tran
Kamran Idrees
Chelsea A. Isom
Ryan C. Fields
Bradley Krasnick
Emily Winslow
Clifford Cho
Robert C. G. Martin
Charles R. Scoggins
Perry Shen
Harveshp D. Mogal
Carl Schmidt
Eliza Beal
Ioannis Hatzaras
Rivfka Shenoy
Shishir K. Maithel
Timothy M. Pawlik
Publication date
01-01-2017
Publisher
Springer International Publishing
Published in
World Journal of Surgery / Issue 1/2017
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-016-3691-y

Other articles of this Issue 1/2017

World Journal of Surgery 1/2017 Go to the issue